Clinical Trials Browser

Phase 1/2 × glumetinib × Clear all

NCT04270591 2022-08-01

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Phase 1/2 Recruiting

C-Met Exon 14 Mutation

NCT04338243 2020-04-08

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Phase 1/2 Unknown

Negative T790M Mutation and Met Amplification